Carisoprodol

Severe dependence after 14 years of continuous use, complicated by acute overdose on presentation.supported

Case of severe carisoprodol withdrawal after 14-year addiction; acute overdose. j.jemermed.2016.11.015

CYP2C19 poor metabolizers face approximately four-fold higher carisoprodol exposure at standard therapeutic dosessupported

CYP2C19 poor metabolizers (3-5% Caucasians/Africans, 15-20% Asians) experience 4-fold increase in carisoprodol exposure. bku002

Carisoprodol abuse documented in North India as an underrecognized phenomenon.supported

Limited literature on clinical profile of subjects abusing carisoprodol; documents abuse in north India. j.genhosppsych.2012.07.011

This genotype has been specifically investigated in fatal carisoprodol intoxications, confirming that genetic variation in drug metabolism contributes to lethal outcomes at doses considered safe for the general population.supported

CYP2C19 mutations investigated in fatal carisoprodol intoxications; conversion to meprobamate almost solely mediated by CYP2C19. s00228-012-1278-6

Blood carisoprodol concentrations exceeding 15 mg/L and liver concentrations exceeding 50 mg/kg may be considered excessive and potentially fatal.supported

Blood carisoprodol >15 mg/L and liver >50 mg/kg may be considered excessive and potentially fatal. bks011

In cases of solo carisoprodol intoxication (no other major contributing drugs), the median blood concentration at death was 36 mg/L (range 8–65 mg/L; n=5).supported

median carisoprodol concentration in solo intoxications 36 mg/L (range 8-65 mg/L, n=5). pmid:17115170

The fatal toxicity index in Norway (1992–2003) was 5.6–6.9 deaths per million defined daily doses — a rate indicating substantial lethality relative to therapeutic use.supported

fatal toxicity index 5.6-6.9 deaths/million DDD. pmid:17115170

Carisoprodol can contribute to death even at therapeutic blood concentrations when combined with other CNS depressants.supported

Carisoprodol can contribute to death even at therapeutic concentrations when combined with other drugs. bks011

Concomitant use with opioids carries an adjusted hazard ratio of 1.84 (95% CI, 1.34–2.54) for opioid overdose compared to opioids alone; risk increases further with combined treatment duration exceeding 60 days (HR 1.80)supported

Carisoprodol showed adjusted HR 1.84 (95% CI 1.34-2.54) for opioid overdose when combined with opioids; risk increased with treatment duration. cpt.1807

This finding was confirmed in an independent cohort studysupported

Concomitant use of prescription opioids and skeletal muscle relaxants associated with opioid overdose; head-to-head safety comparison. wnl.0000000000200904

The 'Holy Trinity' combination (carisoprodol + opioid + benzodiazepine) carries the highest mortality risk, mediated by synergistic respiratory depression across converging GABA-A and μ-opioid pathways.supported

Carisoprodol binds to a unique binding domain within GABA-A receptor to enhance respiratory depressant effects; synergistic increase in dopamine in nucleus accumbens. bcpt.12655

Fatal outcomes have been documented with GHB co-ingestion and in a multidrug case involving sumatriptan (carisoprodol blood level 3.35 mg/L).supported

53-year-old woman fatal accidental combined drug toxicity involving GHB (Xyrem), tramadol, gabapentin, carisoprodol, and modafinil. j.1556-4029.2008.00965.x

Fatal outcomes have been documented with GHB co-ingestion and in a multidrug case involving sumatriptan (carisoprodol blood level 3.35 mg/L).supported

21-year-old female fatality with carisoprodol 3.35 mg/L, meprobamate 2.36 mg/L in central blood, plus multiple other drugs. Cause of death: acute mixed drug toxicity. bku120

Case reports document presentations meeting established serotonin syndrome criteria during carisoprodol intoxication — hyperreflexia, clonus, agitation, diaphoresis — signs inconsistent with pure GABAergic depressionsupported

Four cases of carisoprodol intoxication presenting with serotonergic signs and symptoms meeting three different criteria sets for serotonin syndrome. Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects. pmid:15732445

Case reports document presentations meeting established serotonin syndrome criteria during carisoprodol intoxication — hyperreflexia, clonus, agitation, diaphoresis — signs inconsistent with pure GABAergic depressionsupported

Case of serotonin syndrome with carisoprodol playing a pivotal role; challenges purely GABAergic mechanism of action. bcr-2025-269513

Claim in safety — inconclusiveinconclusiveworking →

Abrupt cessation after prolonged high-dose use can precipitate severe psychiatric symptoms including hallucinations and deliriumsupported

Case of severe carisoprodol withdrawal after 14-year addiction; barbiturate-like GABA-A properties; withdrawal managed with benzodiazepines or antipsychotic agents. j.jemermed.2016.11.015

One case report documents a patient with 14 years of continuous use who experienced both acute overdose and refractory withdrawal sequelae.supported

Case of severe carisoprodol withdrawal after 14-year addiction... acute overdose. j.jemermed.2016.11.015

The dissociation between minimal subjective awareness of impairment and measurable psychomotor deficits at the therapeutic dose (350 mg) is a specific psychological risk: patients may perceive themselves as safe to drive or operate machinery while objectively impaired.supported

350mg: minimal subjective effects but still psychomotor impairment. Therapeutic dose impairing performance without notable subjective effects is a safety concern for driving. j.pbb.2011.08.011

Claim in safety — inconclusiveinconclusiveworking →

Tolerance to carisoprodol's effects has been established in a mouse model via repeated administrationsupported

Repeated administration of carisoprodol produces tolerance and withdrawal signs in a mouse model. j.drugalcdep.2011.10.010

Meprobamate dependence developing secondarily from chronic carisoprodol use.supported

Documents meprobamate dependence arising from carisoprodol use. pmid:8438828

Escalating abuse patterns with carisoprodol as the primary drug of abuse.supported

Small group discovered colluding to obtain carisoprodol under false pretenses for abuse; prior fatality linked to carisoprodol abuse. pmid:8130923

Escalating abuse patterns with carisoprodol as the primary drug of abuse.supported

Carisoprodol (Soma) is a noncontrolled skeletal-muscle relaxant whose active metabolite is meprobamate; three cases demonstrating patterns of abuse. pmid:9439144

Norwegian prescription data showing 15% of patients received ≥75 defined daily doses per year, a utilization pattern consistent with tolerance and dependence; high carisoprodol use was strongly associated with concurrent high use of benzodiazepines and opioids.partially supported

32% received more than 15 DDDs; high users also received more benzodiazepines and opioids; widespread abuse pattern documented. j.1365-2125.2007.02847.x

Abrupt cessation after prolonged high-dose use can produce seizures, delusions, and hallucinationssupported

barbiturate-like GABA-A properties; tolerance and dependence demonstrated in animal model; withdrawal managed with benzodiazepines or antipsychotic agents. j.jemermed.2016.11.015

Standard management employs benzodiazepines (first-line) or antipsychotics; severe cases may be refractory to standard treatment.supported

withdrawal managed with benzodiazepines or antipsychotic agents. j.jemermed.2016.11.015

Opioid co-administration produces an 84% increase in overdose risk (adjusted HR 1.84, 95% CI 1.34–2.54), with risk escalating with treatment durationsupported

Carisoprodol showed adjusted HR 1.84 (95% CI 1.34-2.54) for opioid overdose when combined with opioids; risk increased with treatment duration. cpt.1807

Claim in safety — inconclusiveinconclusiveworking →

The 'Holy Trinity' combination layers GABA-A direct activation (carisoprodol), GABA-A allosteric potentiation (benzodiazepine), and μ-opioid agonism, producing synergistic respiratory depression in medullary centers and synergistic dopamine release in the nucleus accumbenssupported

Carisoprodol binds to a unique binding domain within GABA-A receptor to enhance respiratory depressant effects; synergistic increase in dopamine in nucleus accumbens. bcpt.12655

GHB co-ingestion compounds CNS and respiratory depression; at least one fatality has been documented.supported

53-year-old woman fatal accidental combined drug toxicity involving GHB (Xyrem), tramadol, gabapentin, carisoprodol, and modafinil. j.1556-4029.2008.00965.x

Caution is warranted with all serotonergic agents — SSRIs, SNRIs, MAOIs, tramadol, and triptans — given the documented cases of serotonin syndrome during carisoprodol intoxicationsupported

Four cases of carisoprodol intoxication presenting with serotonergic signs and symptoms meeting three different criteria sets for serotonin syndrome. Important for clinical evaluation and treatment. pmid:15732445

Caution is warranted with all serotonergic agents — SSRIs, SNRIs, MAOIs, tramadol, and triptans — given the documented cases of serotonin syndrome during carisoprodol intoxicationsupported

Case of serotonin syndrome with carisoprodol playing a pivotal role; challenges purely GABAergic mechanism of action. bcr-2025-269513

A fatal multidrug case involving sumatriptan and carisoprodol has been reportedsupported

21-year-old female fatality with carisoprodol 3.35 mg/L, meprobamate 2.36 mg/L in central blood, plus multiple other drugs. Cause of death: acute mixed drug toxicity. bku120

The FDA advises caution and dose adjustment consideration with both classes.supported

FDA label advises caution. bku002

Known CYP2C19 poor metabolizer status: Standard doses produce approximately four-fold higher exposure, with documented fatal outcomes. Alternative muscle relaxants without CYP2C19-dependent metabolism should be used.partially supported

CYP2C19 mutations investigated in fatal carisoprodol intoxications; conversion to meprobamate almost solely mediated by CYP2C19. s00228-012-1278-6

Known CYP2C19 poor metabolizer status: Standard doses produce approximately four-fold higher exposure, with documented fatal outcomes. Alternative muscle relaxants without CYP2C19-dependent metabolism should be used.supported

CYP2C19 poor metabolizers experience 4-fold increase in carisoprodol exposure and 50% decrease in meprobamate; FDA label advises caution. bku002

Concurrent opioid therapy: HR 1.84 for overdose; the benefit-risk ratio does not support co-prescription.supported

Carisoprodol showed adjusted HR 1.84 (95% CI 1.34-2.54) for opioid overdose when combined with opioids. cpt.1807

Concurrent benzodiazepine or alcohol use: Additive GABA-A-mediated CNS and respiratory depression.supported

Carisoprodol binds to a unique binding domain within GABA-A receptor to enhance respiratory depressant effects. bcpt.12655

Concurrent serotonergic agents: Serotonin syndrome documented in case reports; mechanism uncharacterized.supported

Four cases of carisoprodol intoxication presenting with serotonergic signs and symptoms meeting three different criteria sets for serotonin syndrome. Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects. pmid:15732445

Concurrent serotonergic agents: Serotonin syndrome documented in case reports; mechanism uncharacterized.supported

carisoprodol modulates GABA-A but may also have serotonergic activity. bcr-2025-269513

CYP2C19 inhibitor co-administration: Mimics poor metabolizer phenotype; increased carisoprodol exposure.supported

CYP2C19 poor metabolizers experience 4-fold increase in carisoprodol exposure; FDA label advises caution. bku002

Carisoprodol acts as both a positive allosteric modulator (PAM) and a direct gating agonist at GABA-A receptors, distinguishing it from benzodiazepines (purely allosteric modulators) and aligning it pharmacologically with barbituratessupported

Carisoprodol directly activates and allosterically modulates alpha1-beta2-gamma2 GABAARs; subunit-dependent effects. j.neuropharm.2015.04.007

Claim in pharmacology — inconclusiveinconclusiveworking →

These two actions — potentiation of GABA-evoked currents and direct opening of the chloride channel in the absence of GABA — are mediated through distinct binding sites on the receptor complex.supported

Mutation of alpha3 valine at position 440 to leucine significantly increased direct gating effects of carisoprodol without affecting allosteric modulatory effects. TM4 is involved in direct gating but not allosteric modulatory actions. jpet.117.242156

Amino acid volume at this position correlates positively with carisoprodol efficacy, while polarity correlates inverselysupported

Mutation of alpha3 valine at position 440 to leucine significantly increased direct gating effects... alpha1(L415V) decreased carisoprodol direct gating potency and efficacy. jpet.117.242156

At extrasynaptic receptors (α1β3δ and α4β3δ configurations), carisoprodol acts as a direct gating agonist with greater efficacy than GABA itself — a property not shared by most sedative compounds and potentially relevant to its pronounced sedative and abuse-related effects.supported

extrasynaptic receptors show greater efficacy for carisoprodol than GABA. j.neuropharm.2015.04.007

Meprobamate also directly gates and allosterically modulates GABA-A receptors with barbiturate-like activitysupported

Meprobamate (primary metabolite of carisoprodol) modulates GABAA receptors with barbiturate-like activity... direct gating present with all alpha subunits. j.ejphar.2016.02.031

Claim in pharmacology — inconclusiveinconclusiveworking →

Claim in pharmacology — inconclusiveinconclusiveworking →

Claim in pharmacology — inconclusiveinconclusiveworking →

Four cases of carisoprodol intoxication described by Bramness et al. fulfilled three distinct established criteria sets for serotonin syndrome, presenting with hyperreflexia, clonus, agitation, and diaphoresis — signs inconsistent with pure GABAergic depressionsupported

Four cases of carisoprodol intoxication presenting with serotonergic signs and symptoms meeting three different criteria sets for serotonin syndrome. Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects. pmid:15732445

A 2025 case report further documents serotonin toxicity with carisoprodol as the pivotal agentsupported

Case of serotonin syndrome with carisoprodol playing a pivotal role; challenges purely GABAergic mechanism of action. bcr-2025-269513

The combination of carisoprodol with opioids and benzodiazepines — known colloquially as 'the Holy Trinity' — produces synergistic increases in dopamine release in the nucleus accumbens (via μ-opioid-mediated GABA disinhibition layered with GABA-A direct activation) and synergistic respiratory depression in medullary respiratory centerssupported

Carisoprodol binds to a unique binding domain within GABA-A receptor to enhance respiratory depressant effects; synergistic increase in dopamine in nucleus accumbens. bcpt.12655

Claim in pharmacology — inconclusiveinconclusiveworking →

The primary metabolic pathway is CYP2C19-catalyzed N-dealkylation to meprobamate. CYP2C19 poor metabolizers (PM) exhibit approximately four-fold higher carisoprodol exposure and approximately 50% lower meprobamate exposure compared to extensive metabolizerssupported

mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers; N-dealkylation of carisoprodol cosegregates with mephenytoin hydroxylation polymorphism. pmid:8946470

The primary metabolic pathway is CYP2C19-catalyzed N-dealkylation to meprobamate. CYP2C19 poor metabolizers (PM) exhibit approximately four-fold higher carisoprodol exposure and approximately 50% lower meprobamate exposure compared to extensive metabolizerssupported

mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers; N-dealkylation of carisoprodol cosegregates with mephenytoin hydroxylation polymorphism. pmid:8946470

The primary metabolic pathway is CYP2C19-catalyzed N-dealkylation to meprobamate. CYP2C19 poor metabolizers (PM) exhibit approximately four-fold higher carisoprodol exposure and approximately 50% lower meprobamate exposure compared to extensive metabolizerssupported

CYP2C19 poor metabolizers (3-5% Caucasians/Africans, 15-20% Asians) experience 4-fold increase in carisoprodol exposure and 50% decrease in meprobamate; FDA label advises caution. bku002

PM prevalence varies by population: 3–5% among Caucasians and Africans, 15–20% among Asian populations — a clinically significant pharmacogenomic difference that directly affects toxicity risk at standard dosessupported

CYP2C19 poor metabolizers (3-5% Caucasians/Africans, 15-20% Asians) experience 4-fold increase in carisoprodol exposure. bku002

Claim in pharmacology — inconclusiveinconclusiveworking →

Unlike benzodiazepines, which act solely as positive allosteric modulators, carisoprodol functions as both a positive allosteric modulator and a direct gating agonist at GABA-A receptors, producing sedation, muscle relaxation, and dose-dependent psychomotor impairment over a 4–6 hour effective window.partially supported

Carisoprodol directly activates and allosterically modulates alpha1-beta2-gamma2 GABAARs; subunit-dependent effects j.neuropharm.2015.04.007

Ludwig at Wallace Laboratories in the early 1950s as a structural modification of meprobamate, intended to deliver superior muscle relaxation with reduced abuse liabilitysupported

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories. j.1749-6632.1960.tb42792.x

Systematic reviews confirm fair evidence of efficacy for acute low back pain, but adverse CNS effects are significantly more prevalent than with placebo.partially supported

Strong evidence that muscle relaxants are more effective than placebo for acute LBP short-term pain relief; adverse events significantly more prevalent with muscle relaxants. 14651858.cd004252

Carisoprodol's dual GABA-A action — allosteric potentiation (highest at α1-containing receptors) and direct channel gating (with greater-than-GABA efficacy at extrasynaptic α1β3δ and α4β3δ receptors) — produces a barbiturate-like pharmacological profilepartially supported

beta1 confers highest direct activation; beta2 confers highest allosteric modulation; alpha3 shows reduced direct gating; extrasynaptic receptors show greater efficacy for carisoprodol than GABA. j.neuropharm.2015.04.007

CYP2C19 N-dealkylation converts carisoprodol (t½ ~2 hours) to meprobamate (t½ ~10 hours), which itself directly gates and allosterically modulates GABA-A receptors; meprobamate accumulation during repeated dosing contributes substantially to both therapeutic and abuse-related effectssupported

Meprobamate (primary metabolite of carisoprodol) modulates GABAA receptors with barbiturate-like activity... direct gating present with all alpha subunits. j.ejphar.2016.02.031

CYP2C19 N-dealkylation converts carisoprodol (t½ ~2 hours) to meprobamate (t½ ~10 hours), which itself directly gates and allosterically modulates GABA-A receptors; meprobamate accumulation during repeated dosing contributes substantially to both therapeutic and abuse-related effectssupported

15 healthy volunteers: mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers; N-dealkylation of carisoprodol cosegregates with mephenytoin hydroxylation polymorphism. pmid:8946470

The subjective profile is dominated by sedation, anxiolysis, muscle relaxation, and motor impairment, with euphoria reported primarily in abuse contexts; a controlled human study found that even the therapeutic dose (350 mg) produced measurable psychomotor deficits despite minimal subjective awareness of impairment.supported

350mg: minimal subjective effects but still psychomotor impairment. Therapeutic dose impairing performance without notable subjective effects is a safety concern for driving. j.pbb.2011.08.011

Blood concentrations exceeding 15 mg/L are potentially fatal in isolation, and the compound can contribute to death at therapeutic concentrations when combined with other CNS depressantssupported

Blood carisoprodol >15 mg/L and liver >50 mg/kg may be considered excessive and potentially fatal... Carisoprodol can contribute to death even at therapeutic concentrations when combined with other drugs. bks011

Concomitant opioid use increases overdose risk by 84% (adjusted HR 1.84, 95% CI 1.34–2.54)supported

Carisoprodol showed adjusted HR 1.84 (95% CI 1.34-2.54) for opioid overdose when combined with opioids. cpt.1807

Physical and psychological dependence develop rapidly; withdrawal after prolonged use can produce seizures, hallucinations, and deliriumsupported

Case of severe carisoprodol withdrawal after 14-year addiction; barbiturate-like GABA-A properties; withdrawal managed with benzodiazepines or antipsychotic agents. j.jemermed.2016.11.015

Claim in summary — inconclusiveinconclusiveworking →

An unresolved serotonergic mechanism, documented via case reports meeting serotonin syndrome criteria, adds a further layer of clinical complexity.supported

Four cases of carisoprodol intoxication presenting with serotonergic signs and symptoms meeting three different criteria sets for serotonin syndrome. Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects. pmid:15732445

The structural modification was minimal but pharmacologically significant: substitution of one hydrogen on a carbamyl nitrogen with an isopropyl group, yielding a propanediol dicarbamate with the intended advantages of superior muscle relaxation, reduced abuse potential, and greater safety in overdose.supported

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories. j.1749-6632.1960.tb42792.x

Rust et al. documented carisoprodol abuse and fatality cases in 1993, with NIDA data indicating overdose was more common than previously suspectedsupported

Small group discovered colluding to obtain carisoprodol under false pretenses for abuse; prior fatality linked to carisoprodol abuse; NIDA data suggesting overdose more common than suspected. pmid:8130923

Littrell et al. described meprobamate dependence developing secondarily from chronic carisoprodol use, establishing that the metabolite — not merely the parent compound — mediated physical dependencesupported

Documents meprobamate dependence arising from carisoprodol use. pmid:8438828

By the early 2000s, pharmacoepidemiological data from Norway revealed that 15% of carisoprodol patients received 75 or more defined daily doses per year, a utilization pattern consistent with tolerance and dependence.partially supported

53,889 Norwegian women (2.4%) and 29,824 men (1.3%) received carisoprodol in 2004; 32% received more than 15 DDDs. j.1365-2125.2007.02847.x

Norway reclassified carisoprodol to its highest scheduling level on 1 August 2007 and withdrew it from the market entirely on 1 May 2008. Post-withdrawal surveillance confirmed dramatic reductions in DUI cases, forensic autopsies, and poison control contacts involving the drug.supported

Norway reclassified carisoprodol to highest scheduling Aug 2007, withdrawn from market May 2008... Rescheduling and market withdrawal significantly reduced intoxications. j.1742-7843.2009.00459.x

South Korea implemented controls following documented abuse and fatalities.supported

South Korea used urine and postmortem drug testing as early warning system for non-controlled drugs including carisoprodol; accumulated fatality data led to introduction of controls. pmid:21338024

Ludwig at Wallace Laboratories, a division of Carter Products (later Carter-Wallace), in the early 1950ssupported

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories. j.1749-6632.1960.tb42792.x

Claim in history — inconclusiveinconclusiveworking →

Reeves et al. published a case series in 1997 documenting a pattern of escalating carisoprodol abusesupported

Carisoprodol (Soma) is a noncontrolled skeletal-muscle relaxant whose active metabolite is meprobamate; three cases demonstrating patterns of abuse. pmid:9439144

Claim in history — not_supportednot supportedworking →

The controlled human data from Zacny et al. present a dissociation relevant to incentive salience theory: the therapeutic dose (350 mg) produced measurable psychomotor impairment without significantly elevating subjective 'liking' or 'wanting' ratingssupported

350mg: minimal subjective effects but still psychomotor impairment. j.pbb.2011.08.011

Chronic carisoprodol exposure produces GABA-A receptor downregulation and subsensitivity, as demonstrated by tolerance development and precipitated withdrawal in mouse modelssupported

Repeated administration of carisoprodol produces tolerance and withdrawal signs in a mouse model; establishes basis for physical dependence. j.drugalcdep.2011.10.010

What is the molecular target of carisoprodol's serotonergic activity? Clinical serotonin syndrome presentations lack any receptor-level explanation. Is carisoprodol a SERT inhibitor, a direct 5-HT receptor agonist, or does it modulate serotonin release through an indirect mechanism? Resolution of this question has direct treatment implications.supported

Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects. Important for clinical evaluation and treatment. pmid:15732445

What is the molecular target of carisoprodol's serotonergic activity? Clinical serotonin syndrome presentations lack any receptor-level explanation. Is carisoprodol a SERT inhibitor, a direct 5-HT receptor agonist, or does it modulate serotonin release through an indirect mechanism? Resolution of this question has direct treatment implications.supported

challenges purely GABAergic mechanism of action; carisoprodol modulates GABA-A but may also have serotonergic activity. bcr-2025-269513

At extrasynaptic receptors (α1β3δ, α4β3δ configurations), carisoprodol's super-agonist direct gating — exceeding GABA's own maximal efficacy — enhances tonic inhibitionsupported

extrasynaptic receptors show greater efficacy for carisoprodol than GABA. j.neuropharm.2015.04.007

Tonic GABAergic currents regulate baseline neuronal excitability in thalamic relay nuclei, cerebellar granule cells, and hippocampal dentate gyrus; potentiation of these currents produces the generalized psychomotor impairment and sedation documented at therapeutic doses.supported

700mg: VAS ratings of sedation (sleepy, heavy/sluggish feeling), psychomotor impairment. 350mg: minimal subjective effects but still psychomotor impairment. j.pbb.2011.08.011

The relative sparing of α3 circuits may contribute to the preservation of certain arousal functions even under sedation — potentially underpinning the clinically documented phenomenon of delusions of sobriety, wherein users feel subjectively less impaired than objective psychomotor testing reveals.supported

350mg: minimal subjective effects but still psychomotor impairment. Therapeutic dose impairing performance without notable subjective effects is a safety concern for driving. j.pbb.2011.08.011

GABA-A direct activation in the ventral tegmental area (VTA) disinhibits dopaminergic projections to the nucleus accumbens; when layered with μ-opioid-mediated GABA disinhibition (from co-administered opioids), the resulting dopamine surge is synergistic rather than additivesupported

synergistic increase in dopamine in nucleus accumbens. bcpt.12655

This mechanism explains the preferential co-abuse of carisoprodol with opioids and benzodiazepines observed epidemiologically.supported

high users also received more benzodiazepines and opioids; widespread abuse pattern documented. j.1365-2125.2007.02847.x

The clinical evidence for serotonergic activity — serotonin syndrome presentations documented in a case series and a 2025 case report — has not been explained at the receptor levelsupported

Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects. Important for clinical evaluation and treatment. pmid:15732445

The clinical evidence for serotonergic activity — serotonin syndrome presentations documented in a case series and a 2025 case report — has not been explained at the receptor levelsupported

challenges purely GABAergic mechanism of action; carisoprodol modulates GABA-A but may also have serotonergic activity. bcr-2025-269513

Whole-cell patch-clamp studies in HEK293 cells expressing defined GABA-A receptor subunit combinations have delineated the subunit selectivity of carisoprodol's dual mechanism:supported

Carisoprodol directly activates and allosterically modulates alpha1-beta2-gamma2 GABAARs; subunit-dependent effects. j.neuropharm.2015.04.007

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

The β1 subunit confers the highest direct activation efficacy, while γ2 does not significantly modulate this action.supported

beta1 confers highest direct activation. j.neuropharm.2015.04.007

Systematic mutagenesis demonstrates that amino acid side-chain volume at this position correlates positively with carisoprodol direct gating efficacy, and polarity correlates inversely.supported

Mutation of alpha3 valine at position 440 to leucine significantly increased direct gating effects of carisoprodol without affecting allosteric modulatory effects. alpha1(L415V) decreased carisoprodol direct gating potency and efficacy. jpet.117.242156

At extrasynaptic GABA-A receptor configurations (α1β3δ, α4β3δ), carisoprodol produces direct gating currents with greater maximal efficacy than GABA itselfsupported

extrasynaptic receptors show greater efficacy for carisoprodol than GABA. j.neuropharm.2015.04.007

Meprobamate displays its own distinct subunit selectivity profile: allosteric potentiation is largest at α5-containing receptors, and direct gating occurs across all α subunit combinationssupported

Largest effect in alpha5-expressing receptors; direct gating present with all alpha subunits. j.ejphar.2016.02.031

This mechanistic distinction has practical consequences: benzodiazepine overdose alone is rarely fatal due to a ceiling effect on GABA-A potentiation, whereas carisoprodol (and its metabolite meprobamate) can produce fatal respiratory depression as sole intoxicants.supported

Blood carisoprodol >15 mg/L and liver >50 mg/kg may be considered excessive and potentially fatal... Carisoprodol can contribute to death even at therapeutic concentrations when combined with other drugs. bks011

Carisoprodol's allosteric modulation is highest at α1-containing receptors, while meprobamate's allosteric effect peaks at α5-containing receptorspartially supported

beta2 confers highest allosteric modulation; alpha3 shows reduced direct gating. j.neuropharm.2015.04.007

Carisoprodol's allosteric modulation is highest at α1-containing receptors, while meprobamate's allosteric effect peaks at α5-containing receptorssupported

Largest effect in alpha5-expressing receptors. j.ejphar.2016.02.031

Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

The structural difference — a single isopropyl substitution on one carbamate nitrogen — was intended to reduce abuse potential relative to meprobamatesupported

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories. j.1749-6632.1960.tb42792.x

Carisoprodol's additional direct gating action means it can open GABA-A chloride channels independently of GABA — a barbiturate-like property that produces steeper dose-response relationships for sedation and respiratory depressionsupported

Carisoprodol directly activates and allosterically modulates alpha1-beta2-gamma2 GABAARs. j.neuropharm.2015.04.007

The systematic review by Chou et al. compared carisoprodol with cyclobenzaprine and metaxalone for musculoskeletal conditionssupported

Systematic review comparing muscle relaxants; strong evidence for efficacy in acute musculoskeletal pain; carisoprodol compared to other SMRs. j.jpainsymman.2004.05.002

Ralph et al. conducted a double-blind, placebo-controlled randomized trial of carisoprodol 250 mg administered three times daily plus at bedtime for acute lower-back spasmsupported

Placebo-controlled RCT of carisoprodol 250mg TID+QHS for acute lower-back spasm. pmid:18194591

The 350 mg therapeutic dose produced minimal subjective effects but still caused measurable psychomotor impairment on objective tests — a dissociation with direct implications for driving safety, as patients may feel relatively unimpaired while demonstrating quantifiable motor deficitssupported

350mg: minimal subjective effects but still psychomotor impairment. Therapeutic dose impairing performance without notable subjective effects is a safety concern for driving. j.pbb.2011.08.011

Chou et al. conducted a systematic review encompassing 101 randomized controlled trials of skeletal muscle relaxants and concluded that 'fair evidence' supports carisoprodol's efficacy compared to placebo for musculoskeletal conditions, primarily acute back and neck painpartially supported

Systematic review comparing muscle relaxants; strong evidence for efficacy in acute musculoskeletal pain; carisoprodol compared to other SMRs. j.jpainsymman.2004.05.002

The Cochrane review by van Tulder et al. found strong evidence that muscle relaxants as a class are superior to placebo for acute low back pain, but noted that adverse events — particularly CNS effects including drowsiness and dizziness — are significantly more prevalent with active treatment.supported

Strong evidence that muscle relaxants are more effective than placebo for acute LBP short-term pain relief; adverse events significantly more prevalent with muscle relaxants. 14651858.cd004252

Zacny et al. conducted the only published controlled study characterizing subjective and psychomotor effects in healthy volunteerssupported

15 healthy volunteers given 0, 350, and 700 mg carisoprodol. j.pbb.2011.08.011

This pharmacogenomic variability has direct clinical consequences — CYP2C19 poor metabolizer genotypes have been specifically investigated in fatal carisoprodol intoxications, establishing a genetic contribution to lethal outcomes at otherwise standard doses.supported

CYP2C19 mutations investigated in fatal carisoprodol intoxications; conversion to meprobamate almost solely mediated by CYP2C19. s00228-012-1278-6

Data from FDA prescribing information and the original CYP2C19 characterization study.supported

15 healthy volunteers: mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers; N-dealkylation of carisoprodol cosegregates with mephenytoin hydroxylation polymorphism. pmid:8946470

CYP2C19 is the primary enzyme responsible for the N-dealkylation of carisoprodol to meprobamatesupported

N-dealkylation of carisoprodol cosegregates with mephenytoin hydroxylation polymorphism. pmid:8946470

PM prevalence varies by ancestry: 3–5% in Caucasian and African populations, 15–20% in Asian populationssupported

CYP2C19 poor metabolizers (3-5% Caucasians/Africans, 15-20% Asians). bku002

The FDA advises caution and dose adjustment consideration with either class of interactant.supported

FDA label advises caution. bku002

This single substitution distinguishes carisoprodol from meprobamate and confers modestly different pharmacokinetics and receptor subunit selectivity, though both compounds converge at GABA-A receptor targets.supported

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories. j.1749-6632.1960.tb42792.x

The progressive international scheduling of carisoprodol — from uncontrolled pharmaceutical to UN Convention-scheduled substance — traces a regulatory arc driven by a compound that fulfilled none of the safety promises built into its design.supported

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories. j.1749-6632.1960.tb42792.x